Cited by 2,108Blood Pressure and Hypertension StudiesRenal and Vascular PathologiesHormonal Regulation and Hypertension

Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study

Krum, Henry, Schlaich, Markus, Whitbourn, Rob, Sobotka, Paul A, Sadowski, Jerzy, Bartus, Krzysztof, Kapelak, Boguslaw, Walton, Anthony +4 more·2009·The Lancet

Abstract

Background Renal sympathetic hyperactivity is associated with hypertension and its progression, chronic kidney disease, and heart failure. We did a proof-of-principle trial of therapeutic renal sympathetic denervation in patients with resistant hypertension (ie, systolic blood pressure >/=160 mm Hg on three or more antihypertensive medications, including a diuretic) to assess safety and blood-pressure reduction effectiveness.Methods We enrolled 50 patients at five Australian and European centres; 5 patients were excluded for anatomical reasons (mainly on the basis of dual renal artery systems). Patients received percutaneous radiofrequency catheter-based treatment between June, 2007, and November, 2008, with subsequent follow-up to 1 year. We assessed the effectiveness of renal sympathetic denervation with renal noradrenaline spillover in a subgroup of patients. Primary endpoints were office blood pressure and safety data before and at 1, 3, 6, 9, and 12 months after procedure. Renal angiography was done before, immediately after, and 14-30 days after procedure, and magnetic resonance angiogram 6 months after procedure. We assessed blood-pressure lowering effectiveness by repeated measures ANOVA. This study is registered in Australia and Europe with ClinicalTrials.gov, numbers NCT 00483808 and NCT 00664638.Findings In treated patients, baseline mean office blood pressure was 177/101 mm Hg (SD 20/15), (mean 4.7 antihypertensive medications); estimated glomerular filtration rate was 81 mL/min/1.73m(2) (SD 23); and mean reduction in renal noradrenaline spillover was 47% (95% CI 28-65%). Office blood pressures after procedure were reduced by -14/-10, -21/-10, -22/-11, -24/-11, and -27/-17 mm Hg at 1, 3, 6, 9, and 12 months, respectively. In the five non-treated patients, mean rise in office blood pressure was +3/-2, +2/+3, +14/+9, and +26/+17 mm Hg at 1, 3, 6, and 9 months, respectively. One intraprocedural renal artery dissection occurred before radiofrequency energy delivery, without further sequelae. There were no other renovascular complications.Interpretation Catheter-based renal denervation causes substantial and sustained blood-pressure reduction, without serious adverse events, in patients with resistant hypertension. Prospective randomised clinical trials are needed to investigate the usefulness of this procedure in the management of this condition.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(09)60566-3

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Renal sympathetic activation in essential hypertension has been specifically targeted in patients with resistant hypertension by catheter-based renal denervation.

    “Renal sympathetic activation in essential hypertension has been specifically targeted in patients with resistant hypertension by catheter-based renal denervation.103”
  • In drug-resistant essential hypertension, renal nerve ablation lowers blood pressure to a similar degree in normal-weight essential hypertension and obesity-hypertension.

    “In drug-resistant essential hypertension, renal nerve ablation lowers blood pressure to a similar degree in normalweight essential hypertension and obesity-hypertension. 103”
  • Efferent sympathetic renal denervation can be achieved with luminal delivery of radiofrequency and ultrasonic energy.

    “Efferent sympathetic renal denervation can be achieved with luminal delivery of radiofrequency and ultrasonic energy.”
  • Two device-based therapies targeting the sympathetic nervous system were developed: the surgically implanted barostimulator device and catheter-based renal denervation.

    “This was the development of two device-based therapies targeting the sympathetic nervous system, the surgically implanted barostimulator device117 and catheter-based renal denervation20,118.”
  • Among clinical studies of endovascular renal denervation, only in the SYMPLICITY HTN-1 trial was renal denervation confirmed, by measurements of norepinephrine spillover.

    “Among clinical studies of endovascular renal denervation only in the SYMPLICITY HTN-1 trial20 was renal denervation confirmed, by measurements of norepinephrine spillover (release of the transmitter from the renal nerves to plasma).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., Abraham, W. T., & Esler, M.
Affiliations
  • The Alfred Hospital (AU)
  • Baker Heart and Diabetes Institute (AU)
  • St Vincent's Hospital Melbourne (AU)
  • The Ohio State University (US)
  • Jagiellonian University (PL)
  • Cardiovascular Center Frankfurt (DE)
Corresponding author
Krum, Henry
Venue
The Lancet
Publisher
Elsevier BV
Published
2009-04
Volume
373
Issue
9671
Pages
1275-1281
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2115461708
Cited by
2,108
References
31
Citations by year
2026: 32 · 2025: 55 · 2024: 50 · 2023: 72 · 2022: 63 · 2021: 69 · 2020: 79 · 2019: 104 · 2018: 87 · 2017: 122 · 2016: 173 · 2015: 217 · 2014: 323 · 2013: 268 · 2012: 184
FWCI
84.45
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal and Vascular Pathologies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
renal denervation, resistant hypertension, radiofrequency ablation, blood pressure reduction, procedural safety, renal artery dissection, renal artery stenosis, chronic kidney disease, heart failure, antihypertensive medication reduction, office blood pressure, magnetic resonance angiography, renal angiography
MeSH terms
Adult, Aged, Analysis of Variance, Antihypertensive Agents, Diuretics, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Hypertension, Magnetic Resonance Imaging, Male, Middle Aged, Norepinephrine, Radiography, Renal Artery, Safety, Sympathectomy, Treatment Outcome, Catheter Ablation, Blood Pressure Monitoring, Ambulatory

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review